Soares Karen sold $33K of CLOV

Soares Karen (Chief Legal Officer) sold 6,846 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.78 on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Sep 16, 2026, 12:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑planned, offering limited actionable insight.

02

Market read

Minor insider sell with negligible market impact.

03

What to watch

Pre‑arranged 10b5‑1 plan reduces signaling value; holdings remain substantial.

Relevance 2/10Novelty 4/10Timing: filed after market close on 2026-09-15

Background

Form 4 filings disclose insider transactions; traders monitor for potential signals.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Chief Legal Officer sold 6,846 shares for $32,724 via a 10b5-1 plan.

Expected impact

Likely negligible price movement; may cause slight short-term pressure.

Evidence & confidence

Sale represents less than 0.5% of insider holdings and is pre‑arranged, limiting informational value.

Market effects

No material impact on health‑tech sector.

Limited to U.S. market; no broader regional effect.

Not globally relevant.

Counterpoint

Insider could be diversifying; sale does not imply negative outlook.

Key entities

  • Soares Karen

    Chief Legal Officer of Clover Health Investments.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.